1. | dwright29 | |
2. | servigener | |
3. | MAJDAVARAN | |
4. | lucaptr | |
5. | golemelin |
1. | dwright29 | |
2. | servigener | |
3. | MAJDAVARAN | |
4. | lucaptr | |
5. | golemelin |
1. | dwright29 02/12/2018 BeiGene Presents Preliminary Phase 1 Data on Tislelizumab in Patients with Urothelial Carcinoma at 2018 Genitourinary Cancers Symposium |
2. | servigener 01/31/2018 More DD |
3. | golemelin 02/09/2018 Presents preliminary Phase 1 data on Tislelizumab in patients with Urothelial Carcinoma |
4. | dwright29 02/05/2018 Announced the commercial availability of VIDAZA (azacitidine for injection) in China |
5. | golemelin 01/31/2018 Great pipeline with this bio |
6. | waseem0pola 04/11/2018 BeiGene Initiates Global Phase 2 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Previously Treated Hepatocellular Carcinoma |
7. | MAJDAVARAN 09/27/2017 Bios are doing a lot better lately |
8. | servigener 04/10/2018 Announced that the first patient was dosed in a global Phase 2 clinical trial of tislelizumab, an investigat… |
9. | servigener 01/31/2018 Good hopes with $BGNE |
10. | MAJDAVARAN 01/18/2018 Market really liked this>?! |